{"id":22796,"date":"2025-01-24T18:49:05","date_gmt":"2025-01-24T10:49:05","guid":{"rendered":"https:\/\/flcube.com\/?p=22796"},"modified":"2025-01-24T18:49:07","modified_gmt":"2025-01-24T10:49:07","slug":"ascentage-pharma-prices-us-ipo-at-usd-17-25-per-ads","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22796","title":{"rendered":"Ascentage Pharma Prices US IPO at USD 17.25 per ADS"},"content":{"rendered":"\n

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855<\/a>) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker symbol \u201cAAPGV\u201d on a \u201cwhen-issued\u201d basis. Regular-way trading is expected to commence on January 27, 2025, under the ticker symbol \u201cAAPG.\u201d<\/p>\n\n\n\n

Offering Details<\/strong>
The IPO is expected to close on January 28, 2025, and will raise approximately USD 126.4 million for Ascentage Pharma. The offering represents a significant milestone for the company as it seeks to expand its presence in the global biopharmaceutical market. The proceeds from the IPO are expected to support Ascentage Pharma\u2019s ongoing research and development efforts, as well as its commercialization strategy.<\/p>\n\n\n\n

Market Outlook<\/strong>
Ascentage Pharma’s entry into the US market through this IPO underscores the growing interest of Chinese biopharmaceutical companies in tapping into international capital markets. The company\u2019s decision to list on Nasdaq highlights its commitment to enhancing its global profile and attracting a broader investor base. With the funds raised, Ascentage Pharma is well-positioned to advance its pipeline of innovative therapies and strengthen its market position in the biopharmaceutical sector.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public…<\/p>\n","protected":false},"author":1,"featured_media":22797,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[200,985,72,3273],"class_list":["post-22796","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ascentage-pharma","tag-hkg-6855","tag-ipo","tag-nasdaq-aapg"],"yoast_head":"\nAscentage Pharma Prices US IPO at USD 17.25 per ADS - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Ascentage Pharma (HKG: 6855) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker symbol \u201cAAPGV\u201d on a \u201cwhen-issued\u201d basis. Regular-way trading is expected to commence on January 27, 2025, under the ticker symbol \u201cAAPG.\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22796\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma Prices US IPO at USD 17.25 per ADS\" \/>\n<meta property=\"og:description\" content=\"China-based Ascentage Pharma (HKG: 6855) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker symbol \u201cAAPGV\u201d on a \u201cwhen-issued\u201d basis. Regular-way trading is expected to commence on January 27, 2025, under the ticker symbol \u201cAAPG.\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22796\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-24T10:49:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-24T10:49:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2405-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"544\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage Pharma Prices US IPO at USD 17.25 per ADS\",\"datePublished\":\"2025-01-24T10:49:05+00:00\",\"dateModified\":\"2025-01-24T10:49:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796\"},\"wordCount\":220,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2405-png.avif\",\"keywords\":[\"Ascentage Pharma\",\"HKG: 6855\",\"IPO\",\"NASDAQ: AAPG\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22796#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22796\",\"name\":\"Ascentage Pharma Prices US IPO at USD 17.25 per ADS - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2405-png.avif\",\"datePublished\":\"2025-01-24T10:49:05+00:00\",\"dateModified\":\"2025-01-24T10:49:07+00:00\",\"description\":\"China-based Ascentage Pharma (HKG: 6855) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker symbol \u201cAAPGV\u201d on a \u201cwhen-issued\u201d basis. Regular-way trading is expected to commence on January 27, 2025, under the ticker symbol \u201cAAPG.\u201d\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22796\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2405-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2405-png.avif\",\"width\":1080,\"height\":544,\"caption\":\"Ascentage Pharma Prices US IPO at USD 17.25 per ADS\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22796#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma Prices US IPO at USD 17.25 per ADS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage Pharma Prices US IPO at USD 17.25 per ADS - Insight, China's Pharmaceutical Industry","description":"China-based Ascentage Pharma (HKG: 6855) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker symbol \u201cAAPGV\u201d on a \u201cwhen-issued\u201d basis. Regular-way trading is expected to commence on January 27, 2025, under the ticker symbol \u201cAAPG.\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22796","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma Prices US IPO at USD 17.25 per ADS","og_description":"China-based Ascentage Pharma (HKG: 6855) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker symbol \u201cAAPGV\u201d on a \u201cwhen-issued\u201d basis. Regular-way trading is expected to commence on January 27, 2025, under the ticker symbol \u201cAAPG.\u201d","og_url":"https:\/\/flcube.com\/?p=22796","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-24T10:49:05+00:00","article_modified_time":"2025-01-24T10:49:07+00:00","og_image":[{"width":1080,"height":544,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2405-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22796#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22796"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage Pharma Prices US IPO at USD 17.25 per ADS","datePublished":"2025-01-24T10:49:05+00:00","dateModified":"2025-01-24T10:49:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22796"},"wordCount":220,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=22796#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2405-png.avif","keywords":["Ascentage Pharma","HKG: 6855","IPO","NASDAQ: AAPG"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22796#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22796","url":"https:\/\/flcube.com\/?p=22796","name":"Ascentage Pharma Prices US IPO at USD 17.25 per ADS - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=22796#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=22796#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2405-png.avif","datePublished":"2025-01-24T10:49:05+00:00","dateModified":"2025-01-24T10:49:07+00:00","description":"China-based Ascentage Pharma (HKG: 6855) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker symbol \u201cAAPGV\u201d on a \u201cwhen-issued\u201d basis. Regular-way trading is expected to commence on January 27, 2025, under the ticker symbol \u201cAAPG.\u201d","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22796#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22796"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=22796#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2405-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2405-png.avif","width":1080,"height":544,"caption":"Ascentage Pharma Prices US IPO at USD 17.25 per ADS"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22796#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma Prices US IPO at USD 17.25 per ADS"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2405-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22796"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22796\/revisions"}],"predecessor-version":[{"id":22798,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22796\/revisions\/22798"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/22797"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}